Search results
Added:
2 months ago
Source:
Arrhythmia Academy
A new substudy of the VANISH2 trial suggests that for patients with prior myocardial infarction and ventricular tachycardia (VT) who are eligible for sotalol, catheter ablation leads to better outcomes than antiarrhythmic drug (AAD) therapy.¹ For patients eligible only for amiodarone, efficacy was comparable, but amiodarone was associated with a significant increase in adverse events…
View more
Added:
1 day ago
EHRA 2026 — Dr Francesco Santoro joins us to discuss findings from his meta-analysis of randomised controlled trials comparing catheter ablation with anti-arrhythmic drug therapy in patients with ventricular tachycardia and ischaemic heart disease.This meta-analysis pooled data from four RCTs enrolling 947 patients with ischaemic heart disease and ICD implantation, randomised to either catheter…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
A prespecified substudy of the VANISH2 trial suggests first-line catheter ablation is superior to sotalol for reducing arrhythmia events in eligible patients with ischaemic cardiomyopathy and ventricular tachycardia (VT).¹ In patients ineligible for sotalol, ablation showed comparable efficacy to amiodarone but with a markedly better long-term safety profile.MethodologyThe VANISH2 (Ventricular…
View more
Ventricular Tachycardia After Cardioversion
Added:
4 months ago
Case Report
Spatial Autocorrelation Dimension (Di ) in AF
Added:
1 month ago
Review Article
Drug-induced AF
Added:
2 years ago
Review Article
Risk Stratification in Arrhythmogenic Mitral Valve Prolapse
Added:
1 year ago
Review Article